VIP
Research Goal: Analyzing the regulation of cytokine secretion and improvement of blood flow in pulmonary or cerebral research.
Route
Subcutaneous injection
Dose range
50 mcg – 200 mcg
Frequency
Multiple times daily for nasal administration to maintain anti-inflammatory markers
Cycle length
30 days
Overview
Research Goal: Analyzing the regulation of cytokine secretion and improvement of blood flow in pulmonary or cerebral research.
Preparation: Reconstitute with 2.0 mL sterile saline. Often utilized as a nasal spray for direct CNS access.
Studied benefits
- A potent vasodilator and immune modulator
- It is researched for its ability to reduce systemic inflammation, protect lung tissue (especially in cases of CIRS or mold exposure), and improve blood flow
- It also plays a role in regulating the circadian rhythm and gut motility
Reported side effects
- Common side effects include facial flushing, a temporary drop in blood pressure, and a racing heart (tachycardia)
- When used as a nasal spray, it may cause minor nasal congestion or irritation
Protocol
Dosing Schedule (Intranasal / Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
| Method | Dose (mcg) | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Nasal Spray | 50–100 mcg | 4 units (0.04 mL) | + Log |
| Subcutaneous | 200 mcg | 8 units (0.08 mL) | + Log |
Frequency
Multiple times daily for nasal administration to maintain anti-inflammatory markers.
Timing
Evenly spaced intervals throughout the day.
Cycle length
30 days.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
50 doses of 100 mcg per vial
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a balanced diet and stay hydrated to support the Vasoinhibitory Peptide's role in regulating gastrointestinal motility and systemic vasodilation. Engage in regular, moderate exercise to improve circulation and support the peptide’s anti-inflammatory and neuroprotective signaling. Ensure 7–9 hours of quality sleep to facilitate the natural repair of neural and pulmonary tissues. Practice stress management and avoid environmental toxins, as chronic inflammation can interfere with VIP receptor sensitivity and the peptide's ability to modulate the immune response and maintain circadian rhythm homeostasis.
Evidence
Research summaries
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
Findings: Helps open up blood vessels in the lungs, slows down overgrowth of lung cells, and improves breathing for people with a rare lung disease called primary pulmonary hypertension (PPH). In tests, it stopped lung cells from growing too much and made patients feel better without big side effects.
In this study from 2003, doctors tested VIP on patients with PPH, a deadly condition where lung blood pressure gets too high, leading to heart failure. They gave VIP by inhalation (breathing it in) at 200 micrograms a day. It worked by sticking to special spots on lung cells (called VPAC receptors), which were way more active in sick patients. This relaxed the blood vessels and stopped smooth muscle cells in the lungs from multiplying too fast—something that clogs up the lungs in PPH. In lab tests on cells from patients, VIP cut cell growth by up to 50% at certain doses. A small trial on five patients showed it was safe, lowered lung pressure during exercise, and improved life quality. No major side effects like drops in blood pressure happened. This suggests VIP could be a new breathing treatment, easier than other drugs that need IV tubes.
Read the study ↗Therapeutic potential of vasoactive intestinal peptide and its receptors
Findings: Protects brain cells from dying in diseases like Parkinson's, reduces swelling and harmful brain chemicals by calming overactive immune cells in the brain.
This 2010 review looks at VIP's power in brain health. Parkinson's happens when special brain cells that make movement chemical dopamine die off, partly because brain immune cells (microglia) get angry and release toxins. Researchers tested VIP in mouse models of Parkinson's using a brain poison called LPS or MPTP. VIP saved a ton of those dopamine cells—up to 50-70% more survived. How? It turned off the bad microglia through its VPAC1 receiver, cutting poisons like iNOS, IL-1beta, and TNF-alpha (swelling signals). In one test, VIP-treated mice lost way fewer cells in the substantia nigra (the brain spot hit by Parkinson's). Another study confirmed it blocked brain cell death after toxin hits. This points to VIP as a brain protector, maybe slowing Parkinson's or other brain swelling diseases like Alzheimer's. It's exciting because current drugs don't fix the root immune problem well.
Read the study ↗Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Implant osseointegration
Findings: Fights bone loss around dental or joint implants by calming immune overreactions that cause implants to fail. Improves bone healing and sticking.
Implants like fake teeth or hip joints often fail because the body's defense system causes swelling and eats away bone nearby. This 2021 paper explores VIP's role. VIP chills out immune cells and boosts bone-building cells (osteoblasts) while taming bone-breaking ones (osteoclasts). In lab tests, VIP lowered swelling markers and helped cells around implants grow better. It binds to VPAC receptors on bone and immune cells, balancing the fight-or-heal response. Animal studies showed VIP-treated implants stuck to bone stronger with less swelling. For everyday people, this means fewer implant failures—super useful since millions get these each year. Early human clues suggest VIP sprays or coatings could make surgeries safer.
Read the study ↗Immunology of VIP: a review and therapeutical perspectives
Findings: Balances the immune system, fights autoimmune diseases by shifting immune cells from attack mode to calm mode, helps allergies and gut swelling.
VIP is everywhere in the body, especially nerves and gut, acting like a peacekeeper for immunity. This 2001 review from PubMed explains how it stops overactive immune attacks in diseases like allergies, Crohn's, or rheumatoid arthritis. VIP switches "fighter" immune cells (Th1/Th17) to "helper" ones (Th2/Treg) that heal instead of harm. In tests, it cut swelling chemicals like TNF and boosted protectors like IL-10. Lab studies on immune cells showed VIP stopped them from going wild. For patients, this means potential relief from chronic swelling without steroids' bad side effects. It's being eyed for sprays or pills to treat asthma, IBD, or even COVID-like lung storms. Research shows promise in animal mod
Read the study ↗Identification
Chemistry
- cas
- 37221-79-7
- formula
- C₁₄₇H₂₃₈N₄₄O₄₂S (human VIP)
- molecular weight
- 3325.83 Da (or 3326 g/mol)
- source
- Natural; produced by enteric neurons, pancreatic islet cells, and neurons distributed throughout central and peripheral nervous systems
- biosynthesis
- Ribosomal origin; transcribed from VIP gene, translated as larger precursor peptide, then enzymatically processed to mature 28-amino acid peptide
- type
- Linear peptide with no cyclic disulfide bonds
Keep exploring
Related peptides
ARA-290
ARA290 · Cibinetide
- Route
- Subcutaneous
- Dose
- 4 mg – 8 mg
- Cycle
- 4–8 weeks
B7-33
B7-33 peptide · RXFP1 agonist B7-33
- Route
- Subcutaneous
- Dose
- 150 mcg – 500 mcg
- Cycle
- 4–8 weeks for acute fibrosis studies
BPC-157
Bepecin · PL-14736
- Route
- Subcutaneous
- Dose
- 250 mcg – 1 mg
- Cycle
- 8–12 weeks
Bronchogen
AEDL · Ala-Glu-Asp-Leu peptide
- Route
- Subcutaneous
- Dose
- 1 mg – 2 mg
- Cycle
- 10–20 days; often repeated every 4–6 months